Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis

Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis

Abstract Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication for COVID-19, with discordant data on efficacy in reducing mortality risk and disease progression. In the context of a dynamic and rapidly changing pandemic landscape, the utilization of real-world evidenc...

Full description

Bibliographic Details
Main Authors: Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, Stefano Ciriminna, Roberta Papagni, Luca Carruba, Diletta Agnello, Giuseppina De Iaco, Nicolò De Gennaro, Giuseppina Di Franco, Liliana Naro, Gaetano Brindicci, Angelo Rizzo, Davide Fiore Bavaro, Maria Chiara Garlisi, Carmen Rita Santoro, Fabio Signorile, Flavia Balena, Pasquale Mansueto, Eugenio Milano, Lydia Giannitrapani, Deborah Fiordelisi, Michele Fabiano Mariani, Andrea Procopio, Rossana Lattanzio, Anna Licata, Laura Vernuccio, Simona Amodeo, Giacomo Guido, Francesco Vladimiro Segala, Mario Barbagallo, Annalisa Saracino
Format: Article
Language:English
Published: Nature Portfolio 2024-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-59957-w

Internet

https://doi.org/10.1038/s41598-024-59957-w

Similar Items